NextCure falls short of Nasdaq minimum stockholders’ equity requirement
NXTC•NextCure received a Nasdaq notice for having $5.5 million in stockholders’ equity as of September 30, below the $10 million minimum. It must submit a compliance plan by January 4, 2027, unless it regains compliance sooner; a proposed merger with Avere Therapeutics could help restore compliance.
1. Nasdaq compliance notice
NextCure received a Nasdaq noncompliance notice on November 16, 2026, after its stockholders’ equity totaled $5.5 million as of September 30, below the $10 million minimum. It also failed to meet alternative listing standards, and must submit a compliance plan by January 4, 2027, unless compliance is restored before then.
2. Merger and listing status
The proposed merger with Avere Therapeutics, expected in mid-December 2026 subject to stockholder approval and customary conditions, could restore compliance. The notice has no immediate effect on NextCure’s common stock listing or trading on the Nasdaq Global Select Market.




